Prostate Cancer: Page 2

MDxHealth nabs reimbursement for prostate cancer risk test
By LabPulse.com staff writers
The firm's Select mdx test will now be reimbursed in the U.S. for Medicare patients who meet coverage conditions under a specific, foundational Local Coverage Determination (LCD).
April 20, 2023
Cancer Cells Prostate Social
Veracyte announces data for prostate cancer classifier in micrometastatic disease
By LabPulse.com staff writers
The published data show that the Decipher Prostate scores for patients with high-risk and very high-risk disease were highly correlated with the upstaging predictions by a clinically-validated algorithm.
April 17, 2023
Prostate Cancer 3 D Rendering Social
Older males may be overscreened for prostate cancer
By Elissa Wolfson
Researchers have found that older males were often overscreened for prostate cancer, despite national guidelines outlining the limited value of such screening.
April 11, 2023
3 D Prostate Cancer Viral Social
Racial groups negatively impacted by exclusion from cancer research
By Elissa Wolfson
Researchers are calling for greater inclusion of people with African ancestry in genomic research to improve prostate cancer outcome disparities.
March 10, 2023
Prostate Cancer Social
Active surveillance on the rise for low-risk prostate cancer
By Elissa Wolfson
A large study indicates that active surveillance rates for management of low-risk prostate cancer are rising nationally, but are still not optimal.
March 2, 2023
Prostate Cancer Social
Bio-Techne's prostate test granted expanded Medicare coverage
By LabPulse.com staff writers
The updated Medicare policy covers an annual ExoDx Prostate Test for men who have already had a negative biopsy but are thought to be at high risk for prostate cancer and are considering a repeat biopsy.
February 24, 2023
Prostate Cancer 3 D Rendering Social
Cleveland Diagnostics, Quest Diagnostics expand access to blood-based prostate cancer test
By LabPulse.com staff writers
When physicians order the IsoPSA prostate cancer test, their patients will provide blood specimens at a Quest patient service center. Quest will transport the blood samples for testing at a Cleveland Diagnostics’ laboratory.
February 13, 2023
Prostate Cancer Social
Oxford BioDynamics announces study results for prostate screening blood test
By LabPulse.com staff writers
The published results from the multidisciplinary PROSTAGRAM study show that the PSE test had a 92% positive and 94% negative predictive value and an accuracy of 94%.
February 7, 2023
Prostate Cancer Social
In pilot study, liquid biopsy test differentiates between localized and metastatic cancer to inform tailored treatment
By Nick Paul Taylor
Cedars-Sinai Cancer researchers are developing a microfluidic device with a nanosurface as part of a blood test to inform treatment decisions.
February 3, 2023
3 D Prostate Cancer Viral Social
Avenda Health gets FDA 510(k) clearance for iQuest prostate cancer platform
By LabPulse.com staff writers
The iQuest platform provides physicians with a 3D visualization, enabling treatment decisions that consider the extent of the cancer rather than treating the whole organ.
December 8, 2022
Prostate Cancer 3 D Rendering Social
MDxHealth sees Medicare delay for prostate cancer risk test, reduces 2022 revenue guide
By LabPulse.com staff writers
To obtain Medicare payments for the test, the firm had to submit a Technical Assessment for review and consideration under a Local Coverage Decision (LCD) process recently implemented by the Molecular Diagnostics Services (MolDX) Program.
November 30, 2022
3 D Prostate Cancer Viral Social
Low-value prostate cancer screening has Medicare spending ramifications, study finds
By Leo O'Connor
The consequences of low-value PSA cancer screening could amount to more than $275 million in spending for Medicare, according to the authors' estimates.
November 22, 2022
Prostate Cancer Social
Previous Page
Page 2 of 8
Next Page